Skip to main content

CORRECTION article

Front. Cell. Infect. Microbiol., 21 July 2023
Sec. Virus and Host
Volume 13 - 2023 | https://doi.org/10.3389/fcimb.2023.1253110

Corrigendum: Novel molecular therapeutics targeting signaling pathway to control hepatitis B viral infection

This article is a correction to:

  1. Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection

    1. Read original article
Yan Yan*Yan Yan1*Yuanwang QiuYuanwang Qiu1Chantsalmaa DavgadorjChantsalmaa Davgadorj1Chunfu Zheng*Chunfu Zheng2*
  • 1Laboratory for Infection and Immunity, Hepatology Institute of Wuxi, The Fifth People’s Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China
  • 2Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada

A corrigendum on
Novel molecular therapeutics targeting signaling pathway to control hepatitis B viral infection

by Yan Y, Qiu Y, Davgadorj C and Zheng C (2022). Front. Cell. Infect. Microbiol. 12:847539. doi: 10.3389/fcimb.2022.847539

In the published article, there was an error in the affiliations. Instead of three, there are only two affiliations. The original affiliation 2 was removed. The correct affiliations are listed below:

Instead of

Yan Yan1, Yuanwang Qiu1, Chantsalmaa Davgadorj1, Chunfu Zheng2,3

1. “1Laboratory for Infection and Immunity, Hepatology Institute of Wuxi, The Fifth People’s Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.

2. 2Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.

3. 3Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.”, it should be

Yan Yan1, Yuanwang Qiu1, Chantsalmaa Davgadorj1, Chunfu Zheng2

1. “1Laboratory for Infection and Immunity, Hepatology Institute of Wuxi, The Fifth People’s Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.

2. 2Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: HBV, TLR, carcinogenesis, signaling pathway, therapeutics, infection

Citation: Yan Y, Qiu Y, Davgadorj C and Zheng C (2023) Corrigendum: Novel molecular therapeutics targeting signaling pathway to control hepatitis B viral infection. Front. Cell. Infect. Microbiol. 13:1253110. doi: 10.3389/fcimb.2023.1253110

Received: 04 July 2023; Accepted: 06 July 2023;
Published: 21 July 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Yan, Qiu, Davgadorj and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yan Yan, yanyan198134@hotmail.com; Chunfu Zheng, zheng.alan@hotmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.